RADIESSE® LIDOCAINE RECEIVES CE-MARK

RADIESSE® LIDOCAINE with integral 0.3% Lidocaine has received CE-mark and is now available to European physicians. RADIESSE® Lidocaine combines the proven efficacy and safety of RADIESSE® with extra treatment comfort.

Like RADIESSE®, RADIESSE® LIDOCAINE is an injectable dermal filler consisting of calcium hydroxylapatite microspheres suspended in a carboxymethylcellulose gel carrier. Additionally, RADIESSE® LIDOCAINE is enhanced with 0.3 % integral lidocaine hydrochloride.

A study1 proved the efficacy and safety of RADIESSE® LIDOCAINE combined with a significant pain reduction during and throughout the first hour after treatment. For patients, RADIESSE® LIDOCAINE offers significant pain reduction. Physicians benefit because RADIESSE® LIDOCAINE is ready-to-use and patients are satisfied because of a positive treatment experience. Thus, they are more likely to return to the practice.

Press Contact

Merz Pharmaceuticals GmbH
Sophie Charretour
Eckenheimer Landstraße 100
60318 Frankfurt

Email: Sophie.Charretour@merz.com

1) Daniel Schachter. Pain Control Using the Injectable Dermal Filler Calcium Hydroxylapatite with Integral Lidocaine for the Correction of Nasolabial Folds. Poster # 1810. E-POSTER PRESENTATION Saturday, 3/21/2015 from 12:15:00 PM to 12:20:00 PM.